Patient and Caregiver Preferences for Long‐Term Prophylactic Treatment of Bleeds in Haemophilia: A Discrete‐Choice Experiment
Haemophilia · 2026
DOI: 10.1111/hae.70172 ↗Kurz gefasst
Fachartikel in der Zeitschrift Haemophilia, 2026. Verfasst von Hui Lu und 12 weiteren Autor:innen. Beteiligte Einrichtung: PPD Evidera Patient-Centered Research, Thermo Fisher Scientific, London, UK. Hauptthemen laut MEDLINE: Hemophilia A, Caregivers, Patient Preference, Hemorrhage. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer Inc.
Abstract (Originalsprache)
Introduction
The expansion of haemophilia treatment to include non‐factor prophylaxis provides new options with various benefits, risks, administration modes, and device types, necessitating trade‐offs in decision‐making.
Aim
This study evaluated prophylactic treatment preferences of people with haemophilia and their caregivers, assessing their willingness to make trade‐offs among treatment attributes.
Methods
A web‐based survey containing a discrete‐choice experiment (DCE) was completed by adults (≥ 18 years old) and caregivers of children (aged 8–17 years) with haemophilia in the United States and United Kingdom. Participants were asked to complete 10 choice tasks, choosing their preferred prophylaxis from two hypothetical profiles defined by seven attributes. The primary analysis employed a mixed logit model, and subgroup analyses explored preference heterogeneity.
Results
Participants were 194 adults with haemophilia (US: 150; UK: 44) and 169 caregivers (US: 150; UK: 19). Avoiding daily treatment administration had the highest attribute importance among both adults and caregivers, followed by changes in annual bleeds. Participants were willing to accept an increased risk of serious side effects or developing inhibitors, or reduced efficacy in preventing annual bleeds, to switch from intravenous to subcutaneous administration. Refrigeration requirements and the need for a second treatment for breakthrough bleeds had lower importance.
Conclusions
Participants highly value avoiding daily administration and reducing bleeds, and they are willing to accept increased risks or reduced efficacy to have subcutaneous rather than intravenous administration. As new treatments become available, understanding these preferences can facilitate shared decision‐making in treatment selection and enhance patient‐centred drug development and patient communication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- PPD Evidera Patient-Centered Research, Thermo Fisher Scientific, London, UK.
- Pfizer Inc., New York, New York, USA.
- Independent Consultant, London, UK.
- Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, UK.
- Department of Haematology, University College, London, UK.
ORCID-Profile: Travis Gould, Carmine Colavecchia, Joshua Coulter, Lisa J Wilcox, Joseph C Cappelleri, Stephanie A Christopher, Brett Hauber, Pratima Chowdary, Jennifer A Whitty
Förderung
- Pfizer Inc
Zitieren
APA
Lu, H., Gould, T., Colavecchia, C., Coulter, J., Wilcox, L. J., Cappelleri, J. C., Christopher, S. A., Sohn, A., Hauber, B., Gutiérrez-Vargas, Á. A., Dunn, N., Chowdary, P., & Whitty, J. A. (2026). Patient and Caregiver Preferences for Long‐Term Prophylactic Treatment of Bleeds in Haemophilia: A Discrete‐Choice Experiment. Haemophilia. https://doi.org/10.1111/hae.70172
Vancouver
Lu H, Gould T, Colavecchia C, Coulter J, Wilcox LJ, Cappelleri JC, et al. Patient and Caregiver Preferences for Long‐Term Prophylactic Treatment of Bleeds in Haemophilia: A Discrete‐Choice Experiment. Haemophilia. 2026. doi:10.1111/hae.70172
BibTeX
@article{Lu2026,
author = {Lu, Hui and Gould, Travis and Colavecchia, Carmine and Coulter, Joshua and Wilcox, Lisa J and Cappelleri, Joseph C and Christopher, Stephanie A and Sohn, Alexis and Hauber, Brett and Gutiérrez-Vargas, Álvaro A and Dunn, Nicola and Chowdary, Pratima and Whitty, Jennifer A},
title = {Patient and Caregiver Preferences for Long‐Term Prophylactic Treatment of Bleeds in Haemophilia: A Discrete‐Choice Experiment},
journal = {Haemophilia},
year = {2026},
doi = {10.1111/hae.70172}
}
EUVIMED